Extracorporeal CO2 Removal Devices Market Size, Share, Growth, and Industry Analysis, By Type (Extracorporeal CO2 machines,Disposables,Others), By Application (Acute Respiratory Distress Syndrome (ARDS),Chronic Obstructive Pulmonary Disease (COPD),Bridge To Lung Transplant,Others), Regional Insights and Forecast to 2035

Extracorporeal CO₂ Removal Devices Market Overview

The global Extracorporeal CO2 Removal Devices Market is forecast to expand from USD 116.22 million in 2026 to USD 121.47 million in 2027, and is expected to reach USD 172.86 million by 2035, growing at a CAGR of 4.51% over the forecast period.

The Extracorporeal CO₂ Removal Devices Market is anchored in devices that remove carbon dioxide from blood in patients with hypercapnic respiratory failure. In 2024, the extracorporeal CO₂ machines segment held 52.4 % of the market share among device types. Disposables also play a large role due to infection control requirements.

Focusing on the U.S. market specifically, the U.S. extracorporeal CO₂ removal devices market recorded USD 28.6 million in 2022, representing about 36.2 % share of the global market in 2022. The extracorporeal CO₂ machines product segment led in the U.S. in 2022.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:4 % of the device market share in 2024 was from extracorporeal CO₂ machines
• Major Market Restraint:6 % of applications in 2024 centered on bridge-to-transplant, limiting diversification
• Emerging Trends: Venovenous route held over 50 % share in 2024, signaling minimal pump strategies
• Regional Leadership: North America captured roughly 40 % share globally in 2022
• Competitive Landscape: Top two firms command ~30 % of share among seven players
• Market Segmentation: One segment (disposables) exceeds 45 % among types in some forecasts
• Recent Development: A new pump-less arteriovenous module captured ~10 % incremental adoption

Extracorporeal CO₂ Removal Devices Market Latest Trends

In recent years, Extracorporeal CO₂ Removal Devices Market Trends have emphasized lower blood flow operation, modular disposables, and integration with ventilation systems. One trend is that many ECCO₂R systems now operate at flows of 0.4–1.5 L/min, reducing invasiveness while enabling lung-protective ventilation.

Extracorporeal CO₂ Removal Devices Market Dynamics

The Extracorporeal CO₂ Removal Devices Market Dynamics section provides an in-depth evaluation of the internal and external factors shaping the market’s structural development, competitive direction, and clinical adoption rate.

DRIVER

"Rising prevalence of respiratory failure and hypercapnia"

The global burden of chronic obstructive pulmonary disease (COPD) affects over 250 million people worldwide, many of whom develop hypercapnic episodes. Hospitals treating ARDS see mortality rates exceeding 30 %, prompting adoption of adjunct CO₂ removal.

RESTRAINT

"High cost of consumables and reimbursement uncertainty"

Consumable kits for ECCO₂R (oxygenators, tubing, cannulas) often cost hospitals 20–30 % more per case than standard ventilation consumables. Many health systems limit usage because conducted case studies show that 15–20 % of procedures exceed planned budget limits.

OPPORTUNITY

"Emerging markets and home / transport integration"

In Asia-Pacific and Latin America, ventilator capacity is expanding at 8–10 % annually, creating new demand for adjunct CO₂ removal devices. In 2023–2024, hospital builds in India and China increased ICU bed count by ~12 %, marking new potential customers.

CHALLENGE

"Clinical evidence base and safety management"

Despite technological progress, only ~35–40 % of clinical trials involving ECCO₂R report long-term patient survival improvements over ventilator alone. Some studies report up to 8–10 % incidence of hemolysis or thrombosis with extracorporeal circuits. In ARDS patients, the number of enrolled ECCO₂R cases remains low—often fewer than 200 per trial.

Extracorporeal CO2 Removal Devices Market Segmentation

The Extracorporeal CO₂ Removal Devices Market is segmented by type and application. By type, the primary categories are extracorporeal CO₂ machines, disposables, and others. By application, segments include Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Bridge to Lung Transplant, and others.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Extracorporeal CO₂ machines: The extracorporeal CO₂ machines segment commanded 52.4 % of the device market in 2024, making it the dominant type in the Extracorporeal CO₂ Removal Devices Market Report. These machines include pumps, control consoles, and gas exchange modules. Many are engineered to handle blood flows between 0.4 and 1.5 L/min.

The Extracorporeal CO₂ machines segment is forecast to be worth approximately USD 46.7 million in 2025, representing ~42.0% share, and growing at 4.51% CAGR through 2034, driven by rising ICU installations and adoption of advanced CO₂ removal systems across global critical care networks.

Top 5 Major Dominant Countries in the Extracorporeal CO₂ Machines Segment

• United States:expected to reach around USD 14.9 million in 2025, holding approximately 31.9% share, and expanding at a CAGR of ~4.5%, supported by strong clinical infrastructure, large ventilator base, and widespread integration of extracorporeal CO₂ technologies in tertiary care hospitals.
• Germany:anticipated to record USD 5.8 million in 2025, accounting for ~12.4% share, and growing at a CAGR of 4.6%, driven by increasing clinical trials for ARDS and COPD, favorable reimbursement systems, and advanced adoption of extracorporeal CO₂ systems in teaching hospitals.
• Japan:projected to achieve USD 4.2 million in 2025, capturing nearly 9.0% share, with a CAGR of 4.7%, driven by government initiatives promoting critical care modernization, steady adoption of compact extracorporeal modules, and expansion of clinical capacity in large urban hospitals.
• China:expected to be valued at approximately USD 3.9 million in 2025, representing ~8.3% share, and growing at 4.8% CAGR, fueled by large-scale ICU expansion programs, domestic medical device manufacturing, and government funding toward advanced extracorporeal respiratory support infrastructure.
• France:anticipated to reach USD 2.8 million in 2025, securing ~6.0% market share, with an estimated CAGR of 4.4%, supported by increasing ARDS patient volume, adoption of hybrid ventilation and CO₂ removal strategies, and continuous clinical innovation in critical care centers.

Disposables: Disposables—comprising cannulas, oxygenators, tubing, filters—are integral to each ECCO₂R procedure and drive recurring revenue. In many markets, disposables represent 40–55 % of the total unit volume sold, due to single-use standards. For example, oxygenator membrane sets are replaced every 5 days or earlier, and tubing sets are used per patient.

The Disposables segment in the Extracorporeal CO₂ Removal Devices Market is projected to be valued at approximately USD 43.5 million in 2025, representing ~39.1% share, and growing at 4.51% CAGR through 2034, driven by single-use demand, infection control protocols, and consistent replacement cycles across intensive care and transplant facilities.

Top 5 Major Dominant Countries in the Disposables Segment

• United States:expected to reach nearly USD 13.8 million in 2025, holding around 31.7% market share, and growing at a CAGR of 4.5%, driven by high disposable usage rates, frequent replacement intervals, and increased adoption of advanced oxygenator and tubing kits in large hospitals.
• Germany:anticipated to achieve USD 5.5 million in 2025, capturing approximately 12.7% share, with a CAGR of 4.6%, supported by strong procurement networks, stringent infection prevention policies, and growing preference for pre-sterilized single-use CO₂ removal disposables within ICU environments.
• Japan:forecast to record USD 4.0 million in 2025, representing nearly 9.2% share, with a CAGR of 4.7%, driven by enhanced healthcare standards, increased patient throughput in critical care units, and national initiatives promoting single-use disposable devices to minimize cross-contamination.
• China:expected to reach USD 3.7 million in 2025, accounting for about 8.5% share, and expanding at a CAGR of 4.8%, driven by rising ICU construction, government-backed procurement of respiratory disposables, and increased clinical focus on infection safety in tertiary hospitals.
• United Kingdom:projected to generate approximately USD 2.5 million in 2025, representing 5.7% share, with a CAGR of 4.4%, fueled by growing healthcare modernization, strong adoption of high-efficiency disposable oxygenators, and implementation of advanced infection control standards across critical care facilities.

Others: The “others” type includes ancillary items, software modules, sensors, connectors, and accessory modules. This type accounted for ~10–15 % of device shipments in 2023. Examples include integrated sensors for CO₂ concentration, remote telemetry modules, backup pump units, and safety bypass modules. Some providers deliver upgrades—such as advanced CO₂ detection software—to 20 % of installed machines.

The Others segment, comprising sensors, telemetry modules, connectors, and auxiliary components, is estimated to be worth approximately USD 20.9 million in 2025, representing ~18.8% share, and growing steadily at 4.51% CAGR through 2034, driven by integration of monitoring technologies, modular add-ons, and advanced performance optimization features across extracorporeal CO₂ systems.

Top 5 Major Dominant Countries in the Others Segment

• United States:expected to achieve around USD 6.1 million in 2025, capturing nearly 29.2% share, and expanding at a CAGR of 4.5%, supported by rapid adoption of sensor-based modules, continuous device upgrades, and hospital-driven demand for precision monitoring solutions within critical care units.
• Germany:anticipated to reach USD 2.3 million in 2025, representing approximately 11.0% share, with a CAGR of 4.6%, driven by widespread integration of telemetry systems in clinical workflows, government-backed digital health initiatives, and adoption of CO₂ removal performance monitoring interfaces across tertiary hospitals.
• Japan:projected to be valued at USD 1.6 million in 2025, accounting for 7.7% share, and growing at a CAGR of 4.7%, supported by demand for portable control units, clinical preference for compact monitoring devices, and continuous investment in high-precision extracorporeal systems.
• China:forecast to achieve USD 1.5 million in 2025, capturing around 7.2% share, with a CAGR of 4.8%, driven by expansion of ICU digital infrastructure, emerging local manufacturing of modular components, and rapid technological advancement in medical device integration platforms.
• Italy:expected to generate approximately USD 1.0 million in 2025, holding nearly 5.0% share, and growing at a CAGR of 4.4%, fueled by strong adoption of advanced connectors and ancillary kits, expanding medical equipment modernization projects, and specialized applications in multi-organ support devices.

BY APPLICATION

Acute Respiratory Distress Syndrome (ARDS): In ARDS therapy, ECCO₂R is used to reduce ventilator injury by offloading CO₂ removal. In 2024, ARDS applications are forecasted to show fastest growth among applications. Studies show that in severe ARDS patients, ventilator settings can reduce tidal volume by 25–30 % when using ECCO₂R adjunct.

The ARDS application segment is projected to be valued at approximately USD 27.8 million in 2025, representing ~25.0% share, and growing at 4.51% CAGR through 2034, driven by the increasing number of severe respiratory failure cases and adoption of extracorporeal CO₂ removal systems as adjunct therapy to protective lung ventilation.

Top 5 Major Dominant Countries in the ARDS Application

• United States:expected to reach USD 8.7 million in 2025, capturing 31.3% share, and growing at a CAGR of 4.5%, supported by a high incidence of ARDS in intensive care units and growing integration of extracorporeal CO₂ systems for lung-protective ventilation.
• Germany:anticipated to achieve USD 3.1 million in 2025, holding 11.2% share, and expanding at a CAGR of 4.6%, driven by the inclusion of CO₂ removal technologies in clinical protocols for ARDS management and the presence of advanced critical care facilities.
• Japan:projected to record USD 2.4 million in 2025, accounting for 8.6% share, with a CAGR of 4.7%, fueled by increasing ICU admission rates, government focus on ARDS treatment advancements, and the rising demand for advanced extracorporeal systems in tertiary hospitals.
• China:expected to be valued at USD 2.2 million in 2025, representing 7.9% share, and growing at a CAGR of 4.8%, supported by rising hospitalizations for respiratory distress, healthcare reforms improving ICU coverage, and government-backed medical technology investments.
• France:anticipated to reach USD 1.8 million in 2025, capturing 6.5% share, and expanding at a CAGR of 4.4%, driven by the integration of extracorporeal CO₂ systems into ARDS clinical guidelines and the strengthening of hospital networks equipped with advanced respiratory devices.

Chronic Obstructive Pulmonary Disease (COPD): In COPD exacerbations with hypercapnic respiratory failure, ECCO₂R acts as a bridge or adjunct to mechanical ventilation. In forecasts, the share of COPD applications is projected to account for ~25–30 % of use cases. Some hospital series report that in ~30 % of ECCO₂R patients, COPD exacerbation was the primary indication.

The COPD application segment is estimated to be worth approximately USD 30.0 million in 2025, representing ~27.0% share, and growing at 4.51% CAGR through 2034, driven by the global increase in chronic obstructive pulmonary disease prevalence and the adoption of extracorporeal CO₂ removal to manage hypercapnic respiratory failure in severe COPD patients.

Top 5 Major Dominant Countries in the COPD Application

• United States:expected to record USD 9.1 million in 2025, accounting for 30.4% share, and growing at a CAGR of 4.5%, supported by the large COPD patient base, high ICU penetration, and integration of ECCO₂R systems in clinical COPD treatment strategies.
• Germany:anticipated to reach USD 3.4 million in 2025, representing 11.3% share, with a CAGR of 4.6%, driven by advanced pulmonary care centers, high rates of COPD hospitalization, and adoption of minimally invasive extracorporeal solutions in chronic respiratory management.
• Japan:projected to achieve USD 2.6 million in 2025, capturing 8.7% share, and expanding at a CAGR of 4.7%, fueled by a growing elderly population, increasing incidence of chronic respiratory diseases, and healthcare modernization emphasizing innovative respiratory therapies.
• China:forecast to be valued at USD 2.3 million in 2025, holding 7.7% share, and growing at a CAGR of 4.8%, supported by expanding hospital networks, government initiatives for chronic disease management, and rising availability of localized extracorporeal CO₂ technologies.
• United Kingdom:anticipated to generate USD 1.5 million in 2025, securing 5.0% share, with a CAGR of 4.4%, driven by clinical expansion of ECCO₂R use in severe COPD cases and increasing emphasis on reducing invasive ventilation dependency.

Bridge To Lung Transplant: Bridge to lung transplant is the lead single application segment: in 2024, this segment accounted for ~39.6 % of usage among clinical categories. Many transplant centers report that 3 to 4 out of every 10 patients awaiting donor lungs are supported using ECCO₂R to control hypercapnia. This usage is especially common in patients who cannot be fully ventilated or oxygenated via mechanical ventilation.

The Bridge to Lung Transplant segment is projected to be valued at approximately USD 40.0 million in 2025, representing ~36.0% share, and growing at 4.51% CAGR through 2034, driven by the rising number of end-stage lung disease patients awaiting transplant and the increasing use of extracorporeal CO₂ systems as bridging therapy.

Top 5 Major Dominant Countries in the Bridge to Lung Transplant Application

• United States:expected to reach USD 13.2 million in 2025, capturing 33.0% share, and expanding at a CAGR of 4.5%, supported by the large number of transplant centers and high adoption of extracorporeal CO₂ devices in pre-transplant respiratory support.
• Germany:projected to achieve USD 5.2 million in 2025, holding 13.0% share, and growing at a CAGR of 4.6%, driven by established lung transplant programs, government funding for advanced respiratory care, and expansion of extracorporeal therapy facilities in university hospitals.
• Japan:anticipated to record USD 3.7 million in 2025, representing 9.3% share, and growing at a CAGR of 4.7%, fueled by an increasing number of transplant procedures, improved post-transplant survival rates, and adoption of advanced CO₂ management systems.
• China:expected to be valued at USD 3.3 million in 2025, capturing 8.3% share, and growing at a CAGR of 4.8%, driven by rapid healthcare infrastructure development, expansion of transplant capabilities, and increasing government investment in respiratory device technology.
• Italy:forecast to generate USD 1.8 million in 2025, representing 4.5% share, with a CAGR of 4.4%, supported by growing lung transplant activity, favorable clinical outcomes using extracorporeal CO₂ systems, and specialized hospital expansion across key metropolitan regions.

Others: The “others” application category includes perioperative use, sepsis-induced hypercapnia, acute exacerbations of asthma, and transport/emergency applications. These cases represent ~5–10 % of total ECCO₂R volume. Some clinicians trial ECCO₂R in status asthmaticus, with CO₂ reduction of 15–20 mmHg over several hours.

The Others application segment, covering perioperative, transport, and sepsis-related use, is forecast to reach approximately USD 13.4 million in 2025, representing ~12.0% share, and growing at 4.51% CAGR through 2034, driven by expansion in emergency medicine, portable ICU systems, and short-term extracorporeal interventions.

Top 5 Major Dominant Countries in the Others Application

• United States:expected to record USD 4.3 million in 2025, representing 32.1% share, and expanding at a CAGR of 4.5%, supported by strong adoption in emergency and mobile ICU environments, and advanced protocols for perioperative respiratory management.
• Germany:anticipated to achieve USD 1.4 million in 2025, capturing 10.4% share, with a CAGR of 4.6%, driven by widespread deployment of transport-compatible ECCO₂R units and integration of extracorporeal CO₂ systems in multidisciplinary critical care applications.
• Japan:projected to be valued at USD 1.1 million in 2025, representing 8.3% share, and growing at a CAGR of 4.7%, supported by increased mobile healthcare capability, rapid response systems adoption, and medical transport digitization efforts.
• China:forecast to generate USD 1.0 million in 2025, holding 7.5% share, and expanding at a CAGR of 4.8%, driven by emergency response advancements, improved hospital logistics, and technological adaptation of portable extracorporeal devices for critical interventions.
• Spain:expected to reach USD 0.6 million in 2025, capturing 4.5% share, and growing at a CAGR of 4.4%, supported by emergency medicine reforms, hospital collaboration networks, and the introduction of compact extracorporeal units for high-acuity patient management.

Regional Outlook for the Extracorporeal CO2 Removal Devices Market

The global Extracorporeal CO₂ Removal Devices Market exhibits distinct regional performance. North America leads with ~40 % share, Europe holds second place (~25–30 %), Asia-Pacific is fastest growing (~7–8 % adoption growth annually), and Middle East & Africa (MEA) remains nascent (<5 % share).

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America, the extracorporeal CO₂ removal devices market has maintained a dominant position, capturing approximately 40 % of global market share in 2022. The U.S. alone contributed ~36.2 % of global footprint in that year. The U.S. market registered USD 28.6 million in 2022, with extracorporeal CO₂ machines being the top product segment.

North America:is projected to hold approximately USD 45.0 million in 2025, representing nearly 40.5% of the global market share, and growing at 4.51% CAGR through 2034, driven by advanced healthcare infrastructure, widespread ICU capacity, and early adoption of innovative extracorporeal CO₂ removal devices across hospitals and research institutes.

North America - Major Dominant Countries in the Extracorporeal CO₂ Removal Devices Market

• United States:expected to reach around USD 36.4 million in 2025, capturing approximately 81.0% share, and expanding at a CAGR of 4.5%, supported by high hospital adoption rates, leading transplant centers, and strong clinical integration of ECCO₂R systems nationwide.
• Canada:anticipated to achieve USD 5.6 million in 2025, holding 12.4% share, and growing at a CAGR of 4.7%, driven by strategic investments in respiratory care, expansion of tertiary hospitals, and strong government initiatives in critical care innovation.
• Mexico:projected to record USD 1.0 million in 2025, representing 2.2% share, and growing at a CAGR of 4.8%, fueled by healthcare infrastructure development, government health reforms, and the establishment of new intensive care units across major cities.
• Cuba:expected to reach USD 0.5 million in 2025, accounting for 1.1% share, and expanding at a CAGR of 4.4%, supported by increased focus on medical modernization, intensive care training, and adoption of cost-efficient CO₂ management systems.
• Panama:anticipated to generate USD 0.4 million in 2025, representing 0.9% share, with a CAGR of 4.5%, driven by expanding hospital infrastructure, adoption of portable extracorporeal systems, and rising regional collaboration in critical respiratory care solutions.

EUROPE

Europe represents the second most significant region in the Extracorporeal CO₂ Removal Devices Market, often holding ~25–30 % share in recent years. The European landscape benefits from robust public healthcare systems, reimbursement frameworks, and established transplant and ARDS networks across Germany, France, UK, Italy, and Spain. In 2022–2024, European adoption of ECCO₂R systems expanded by ~10–12 % annually in metropolitan hospital hubs.

Europe:is projected to reach approximately USD 30.0 million in 2025, representing about 27.0% share of the global market, and growing at 4.51% CAGR through 2034, supported by well-established transplant networks, advanced ICU systems, and strong government funding for extracorporeal CO₂ removal devices.

Europe - Major Dominant Countries in the Extracorporeal CO₂ Removal Devices Market

• Germany:expected to record USD 6.0 million in 2025, representing 20.0% share, and expanding at a CAGR of 4.6%, driven by increasing research activities, strong hospital procurement programs, and significant integration of extracorporeal systems in respiratory units.
• United Kingdom:anticipated to reach USD 4.2 million in 2025, holding 14.0% share, and growing at a CAGR of 4.5%, fueled by NHS investments, rising COPD and ARDS cases, and hospital collaborations for advanced respiratory care technology adoption.
• France:projected to achieve USD 3.8 million in 2025, capturing 12.7% share, and growing at a CAGR of 4.4%, driven by enhanced ARDS management frameworks, modernized intensive care units, and increasing funding for extracorporeal support technology research.
• Italy:expected to be valued at USD 3.0 million in 2025, representing 10.0% share, and expanding at a CAGR of 4.3%, supported by government initiatives in respiratory care, growing transplant infrastructure, and clinical innovation in extracorporeal CO₂ devices.
• Spain:anticipated to generate USD 2.5 million in 2025, capturing 8.3% share, and growing at a CAGR of 4.4%, driven by rising ARDS admissions, public hospital upgrades, and strong cross-border cooperation in critical care technology development.

ASIA-PACIFIC

The Asia-Pacific region is emerging as a high-growth frontier in the Extracorporeal CO₂ Removal Devices Market. Although its current share lags behind North America and Europe, its adoption growth rates are the highest—regional analyses suggest ~7–8 % annual increase in installed ECCO₂R systems. In 2023, Asia-Pacific accounted for ~15–20 % of new system orders globally.

Asia:is projected to be valued at approximately USD 22.0 million in 2025, representing around 19.8% of the total market share, and growing at 4.51% CAGR through 2034, fueled by rapid healthcare expansion, increased ICU capacity, and government support for critical respiratory device deployment.

Asia - Major Dominant Countries in the Extracorporeal CO₂ Removal Devices Market

• China:expected to record USD 7.1 million in 2025, representing 32.3% share, and growing at a CAGR of 4.8%, driven by healthcare infrastructure expansion, localization of device manufacturing, and increased adoption in urban tertiary hospitals.
• Japan:anticipated to reach USD 4.0 million in 2025, capturing 18.2% share, and growing at a CAGR of 4.7%, supported by advanced medical technology integration, government research funding, and the presence of key respiratory care centers.
• India:projected to achieve USD 3.5 million in 2025, representing 15.9% share, and expanding at a CAGR of 4.9%, fueled by large COPD and ARDS patient populations, hospital construction, and national health initiatives for intensive care development.
• South Korea:expected to generate USD 2.2 million in 2025, capturing 10.0% share, and growing at a CAGR of 4.6%, driven by rapid hospital digitization, increased clinical trials, and adoption of hybrid extracorporeal support systems.
• Australia:anticipated to reach USD 1.2 million in 2025, holding 5.5% share, and expanding at a CAGR of 4.5%, supported by rising demand in transplant programs, strong academic collaborations, and implementation of portable CO₂ removal systems in critical units.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region is nascent in the Extracorporeal CO₂ Removal Devices Market, currently representing under 5 % of global share. ECCO₂R systems are installed primarily in flagship government or academic hospitals in GCC, South Africa, and selected North African facilities. In 2023–2024, only ~10–15 hospitals across the region had active ECCO₂R programs.

Middle East and Africa:is forecast to be valued at approximately USD 14.2 million in 2025, representing around 12.8% of global share, and growing at 4.51% CAGR through 2034, driven by healthcare modernization, ICU expansion projects, and increasing government investment in respiratory support systems.

Middle East and Africa - Major Dominant Countries in the Extracorporeal CO₂ Removal Devices Market

• Saudi Arabia:expected to reach USD 4.0 million in 2025, representing 28.2% share, and growing at a CAGR of 4.6%, supported by advanced hospital infrastructure, national health funding, and adoption of extracorporeal CO₂ removal in tertiary care centers.
• United Arab Emirates:anticipated to achieve USD 3.5 million in 2025, capturing 24.6% share, and growing at a CAGR of 4.5%, driven by high investment in advanced medical technologies, ICU expansion, and increasing clinical use of hybrid respiratory systems.
• South Africa:projected to record USD 2.2 million in 2025, representing 15.5% share, and expanding at a CAGR of 4.7%, supported by established academic hospitals, public health initiatives, and growing utilization of CO₂ removal devices in teaching institutions.
• Egypt:expected to be valued at USD 1.5 million in 2025, holding 10.6% share, and growing at a CAGR of 4.8%, fueled by critical care development, government hospital upgrades, and international collaborations in medical equipment procurement.
• Nigeria:anticipated to generate USD 1.0 million in 2025, capturing 7.0% share, and growing at a CAGR of 4.9%, driven by expanding healthcare budgets, improved ICU access, and gradual introduction of portable extracorporeal systems in regional hospitals.

List of Top Extracorporeal CO₂ Removal Devices Companies

• Getinge AB
• Medtronic
• Alung Technologies
• Xenios AG
• Aferectica Srl
• ESTOR S.P.A
• Medica Spa

Getinge AB: Getinge, through its Xenios AG subsidiary, is among the top two in market share, commanding approximately 12–15 % of units in major markets

Medtronic: Medtronic is the second major company, contributing ~10–13 % of ECCO₂R device shipments globally

Investment Analysis and Opportunities

Investment attention in the Extracorporeal CO₂ Removal Devices Market is increasing as medical device funds and strategic health systems seek stable recurring streams. In recent years, about 20–25 % of new device funding rounds in respiratory tech have involved ECCO₂R companies. Venture and growth capital injections in ECCO₂R startups surged ~30 % year over year between 2021 and 2024.

New Product Development

In the Extracorporeal CO₂ Removal Devices Market, new product development is heavily focused on miniaturization, integration, and smarter control systems. Several manufacturers are designing portable ECCO₂R modules capable of handling flows from 0.3 to 1.5 L/min in compact enclosures fitting on standard ICU carts.

Five Recent Developments

• In 2023, Xenios AG launched a next-generation membrane oxygenator with 25 % higher CO₂ elimination capacity in pilot use.
• In 2024, Getinge AB upgraded its Xenios module firmware to include closed-loop sweep gas control, adopted in ~10 hospitals.
• In 2024, Medtronic introduced an ECCO₂R add-on module to its existing ECMO platforms, increasing dual-module sales by ~8 %.
• In 2025, Alung Technologies obtained expanded regulatory clearance for its Hemolung system to operate at lower flow (0.4 L/min), broadening COPD application.
• In 2025, a consortium of hospitals in Europe announced a multicenter trial deploying pump-less arteriovenous CO₂ removal systems in 120 ARDS patients, targeting 10 % adoption in study sites.

Report Coverage of Extracorporeal CO₂ Removal Devices Market

The Report Coverage in the Extracorporeal CO₂ Removal Devices Market Research Report spans detailed revenue and unit forecasts, segmentation by product type, application, access (venovenous vs arteriovenous), end-use (hospitals, clinics, ambulatory), and region. It includes historical data for 2018–2024, and forward projections to 2030 or beyond.

Extracorporeal CO2 Removal Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 116.22 Million in 2026
Market Size Value By	USD 172.86 Million by 2035
Growth Rate	CAGR of 4.51% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Extracorporeal CO2 machines Disposables Others By Application : Acute Respiratory Distress Syndrome (ARDS) Chronic Obstructive Pulmonary Disease (COPD) Bridge To Lung Transplant Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample